These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 29693175)

  • 1. Microvesicles shed from bortezomib-treated or lenalidomide-treated human myeloma cells inhibit angiogenesis in vitro.
    Guo HM; Sun L; Yang L; Liu XJ; Nie ZY; Luo JM
    Oncol Rep; 2018 Jun; 39(6):2873-2880. PubMed ID: 29693175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum deprivation elevates the levels of microvesicles with different size distributions and selectively enriched proteins in human myeloma cells in vitro.
    Sun L; Wang HX; Zhu XJ; Wu PH; Chen WQ; Zou P; Li QB; Chen ZC
    Acta Pharmacol Sin; 2014 Mar; 35(3):381-93. PubMed ID: 24374813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis.
    Zarfati M; Avivi I; Brenner B; Katz T; Aharon A
    Angiogenesis; 2019 Feb; 22(1):185-196. PubMed ID: 30386953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib inhibits the angiogenesis mediated by mesenchymal stem cells.
    Wang X; Zhang Z; Yao C
    Cancer Invest; 2012 Nov; 30(9):657-62. PubMed ID: 23013101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
    De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
    Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrahydroisoquinoline reduces angiogenesis by interacting myeloma cells with HUVECs mediated by extracellular vesicles.
    Kooshari A; Shahriyary F; Shahidi M; Vafajoo M; Amirzargar MR
    Med Oncol; 2024 Aug; 41(9):217. PubMed ID: 39102060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microvesicles secreted from human multiple myeloma cells promote angiogenesis.
    Liu Y; Zhu XJ; Zeng C; Wu PH; Wang HX; Chen ZC; Li QB
    Acta Pharmacol Sin; 2014 Feb; 35(2):230-8. PubMed ID: 24374814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications.
    Gupta D; Treon SP; Shima Y; Hideshima T; Podar K; Tai YT; Lin B; Lentzsch S; Davies FE; Chauhan D; Schlossman RL; Richardson P; Ralph P; Wu L; Payvandi F; Muller G; Stirling DI; Anderson KC
    Leukemia; 2001 Dec; 15(12):1950-61. PubMed ID: 11753617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimyeloma effects of resveratrol through inhibition of angiogenesis.
    Hu Y; Sun CY; Huang J; Hong L; Zhang L; Chu ZB
    Chin Med J (Engl); 2007 Oct; 120(19):1672-7. PubMed ID: 17935668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fucoidan inhibits angiogenesis induced by multiple myeloma cells.
    Liu F; Luo G; Xiao Q; Chen L; Luo X; Lv J; Chen L
    Oncol Rep; 2016 Oct; 36(4):1963-72. PubMed ID: 27498597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.
    de Oliveira MB; Fook-Alves VL; Eugenio AIP; Fernando RC; Sanson LFG; de Carvalho MF; Braga WMT; Davies FE; Colleoni GWB
    Cancer Lett; 2017 Sep; 403():206-215. PubMed ID: 28645562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PO-45 - The role of microvesicles in multiple myeloma progression.
    Zarfati M; Katz T; Avivi I; Brenner B; Aharon A
    Thromb Res; 2016 Apr; 140 Suppl 1():S193. PubMed ID: 27161734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipose-Derived Stem Cells Induce Angiogenesis via Microvesicle Transport of miRNA-31.
    Kang T; Jones TM; Naddell C; Bacanamwo M; Calvert JW; Thompson WE; Bond VC; Chen YE; Liu D
    Stem Cells Transl Med; 2016 Apr; 5(4):440-50. PubMed ID: 26933040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effects of multiple myeloma cells and tumor-associated macrophages on vascular endothelial cells in vitro.
    Sun M; Qiu S; Xiao Q; Wang T; Tian X; Chen C; Wang X; Han J; Zheng H; Shou Y; Chen K
    Med Oncol; 2020 Oct; 37(11):99. PubMed ID: 33040185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.
    Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T
    Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of parthenolide on the angiogenesis induced by human multiple myeloma cells and the mechanism.
    Kong F; Chen Z; Li Q; Tian X; Zhao J; Yu K; You Y; Zou P
    J Huazhong Univ Sci Technolog Med Sci; 2008 Oct; 28(5):525-30. PubMed ID: 18846331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
    Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
    Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
    Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
    Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic markers in plasma cell myeloma patients treated with novel agents.
    Medinger M; Halter J; Heim D; Buser A; Gerull S; Stern M; Passweg J
    Anticancer Res; 2015 Feb; 35(2):1085-90. PubMed ID: 25667497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis.
    Sanda T; Kuwano T; Nakao S; Iida S; Ishida T; Komatsu H; Shudo K; Kuwano M; Ono M; Ueda R
    Leukemia; 2005 Jun; 19(6):901-9. PubMed ID: 15843826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.